Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 20/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13378117 | 0.88 | FFAR4 (0.50) | FFAR4 | |
| SCHEMBL2888198 | 0.88 | FFAR4 (0.50) | FFAR4 | |
| Hydrochloric Acid SCHEMBL2882694 | 0.88 | FFAR4 (0.49) | FFAR4 | |
| SCHEMBL14270624 | 0.87 | FFAR4 (0.49) | FFAR4 | |
| SCHEMBL4938902 | 0.86 | FFAR4 (0.51) | FFAR4 | |
| SCHEMBL14270632 | 0.85 | FFAR4 (0.52) | FFAR4 | |
| SCHEMBL14270621 | 0.84 | RXRA (0.48) | FFAR4 | |
| SCHEMBL14270626 | 0.84 | FFAR4 (0.47) | FFAR4 | |
| SCHEMBL14270625 | 0.84 | FFAR4 (0.47) | FFAR4 | |
| SCHEMBL14270650 | 0.83 | FFAR4 (0.47) | FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368302-B1 | NOVEL AMINO DICARBOXYLIC ACID DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2008-09-10 | — | — | EP | disclosed |
| US-7329777-B2 | Methods for treating heart failure, thromboembolic disorders, and pulmonary fibrosis | BAYER AKTIENGESELLSCHAFT (DE) | 2008-02-12 | — | — | US | disclosed |
| US-7329777-B2 | Methods for treating heart failure, thromboembolic disorders, and pulmonary fibrosis | BAYER AKTIENGESELLSCHAFT (DE) | 2008-02-12 | — | — | US | disclosed |
| US-7329777-B2 | Methods for treating heart failure, thromboembolic disorders, and pulmonary fibrosis | BAYER AKTIENGESELLSCHAFT (DE) | 2008-02-12 | — | — | US | disclosed |
| US-20050288366-A1 | Novel aminodicarboxylic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-12-29 | — | — | US | disclosed |
| US-6939990-B2 | Derivatives of dicarboxylic acid having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2005-09-06 | — | — | US | disclosed |
| US-20040110840-A1 | Novel derivatives of dicarboxylic acid having pharmaceutical properties | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110840-A1 | Novel derivatives of dicarboxylic acid having pharmaceutical properties | SDHA, GOT2, MDH2 | FFAR4 806/4885 |
| US-20050288366-A1 | Novel aminodicarboxylic acid derivatives | DDC, DAO, AADAT | FFAR4 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.